Our findings thus show that cTnI measurements from a routine clinical biochemistry laboratory can be used to identify a smaller proportion of lung cancer screening participants at elevated risk of cardiac death (e.g., about 5 percent of participants with 10-year risk of close to 5%) who were previously unaware of being at elevated risk, and who could be offered preventive treatment. The gene discussed is TNNI3; the disease is lung cancer.